VRDN Q4 2019 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$880,000+84.9% YoY

Gross Profit

-$6M-629.2% margin

Operating Income

-$10M-1144.4% margin

Net Income

-$10M-1149.8% margin

EPS (Diluted)

$-4.69

QoQ Revenue Growth

+26.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$30M

Total Liabilities

$15M

Stockholders' Equity

$16M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$880,000	$476,000	+84.9%
Gross Profit	-$6M	-$8M	+28.6%
Operating Income	-$10M	-$10M	+3.7%
Net Income	-$10M	-$10M	+1.9%

Revenue Segments

Reimbursement Revenue

$837,00049%

Collaboration Revenue

$837,00049%

Grant

$43,0003%